Type6 Therapeutics Inc. has disclosed cyclin-dependent kinase 2 (CDK2) inhibitors reported to be useful for the treatment of cancer, neurodegeneration, autoimmune disease and inflammatory disorders.
Tumor protein p73 (TP73) has been commonly tagged as a putative tumor suppressor, but it may positively regulate the growth and stemness of cancer stem cells.
Transient receptor potential canonical (TRPC) channels are known to play a key role in regulating nervous system excitability and they have been previously implicated in seizure development.
A recent article by researchers from Hangzhou Medical College reports data from studies that aimed to investigate the mechanisms behind the antitumor activity of the synthetic retinoid analogue WYC-209.
CTNNB1 syndrome is a neurodevelopmental disorder characterized by intellectual disability, global developmental delay, microcephaly and motor disabilities, among others, caused by pathogenic loss-of-function variants in the CTNNB1 gene, which encodes β-catenin. This syndrome has no treatment option, with only supportive care available. To address this unmet medical need, researchers from the Broad Institute and Tufts University School of Biomedical Sciences have developed a Ctnnb1 germline heterozygote murine model that mimics the human CTNNB1 syndrome.
Recent research indicates that CDC42 plays a role in the pathogenesis of kidney disorders such as congenital nephrotic syndrome or glomerulosclerosis because it is necessary for the correct function of renal podocyte and tubule.
Keros Therapeutics Inc. has presented preclinical data on the activin receptor type IIB ligand trap RKER-012 (a research version of KER-012 [cibotercept]) in a preclinical pulmonary arterial hypertension model.
Plexium Inc. has described the efforts that led to the discovery of PLX-4545, an orally bioavailable molecular glue degrader of IKZF2 for the treatment of cancer that is currently undergoing evaluation in a phase I study in healthy volunteers.
Microbiotica Ltd. is poised to advance two of its microbiome-derived products into the clinic after securing regulatory approval and fresh finance. The first live bacterial therapeutic, MB-097, will be tested in combination with Keytruda (pembrolizumab) in patients with advanced melanoma who have not responded to treatment with immune checkpoint inhibitors. The second product, MB-310, is a once-daily oral therapy for treating the inflammatory bowel disease, ulcerative colitis.
RSS
